Life BioSciences has announced a significant milestone with the first patient dosed in a Phase 1 clinical trial for ER-100, an epigenetic restoration drug candidate. This drug targets optic neuropathies, a group of disorders that damage the optic nerve and can lead to permanent vision loss. The trial will assess the safety and tolerability of ER-100, while also evaluating its impact on visual function. AI
RANK_REASON The cluster reports on the initiation of a Phase 1 clinical trial for a new drug candidate, which falls under research. [lever_c_demoted from research: ic=1 ai=0.1]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
